Get more Radiology AI news with our free newsletter.

By signing up you content to our privacy policy

Syntermed is first U.S. distributor of Pylarify AI

Lantheus received approval from the U.S. Food and Drug Administration (FDA) in May 2021 for Pylarify (F-18 DCFPyL), a PET radiotracer that targets PSMA, with clearance for Pylarify AI following in July.

Pylarify AI uses a deep-learning algorithm that has been trained and validated on more than 3,000 images. It allows healthcare professionals and researchers to perform standardized quantitative assessment of PSMA-PET/CT images.

PSMA is a protein expressed on prostate cancer cells. Imaging and quantifying PSMA in patients with suspected prostate cancer can help clinicians determine…

Go to publisher site for the complete article:

Read More

Radiology AI
Compare items
  • Total (0)